The study demonstrated the non-inferiority of NTC014 - antibiotic and NSAID-compared to an antibiotic alone for bacterial conjunctivitis, despite a lower dose of antibiotic. This drug fulfills NTC's mission to rationalize the use of antibiotics.
In the interview with Life Science Review, NTC CEO Riccardo Carbucicchio highlighted NTC's commitment to producing drugs that fill patients' unmet medical needs...
The deal represents an important step for the internationalization of NTC015, developed to address unmet medical needs and improve patient compliance.
NTC, an international pharmaceutical company headquartered in Milan, Italy, announced today to have embraced a strategic partnership with Silgan Dispensing Systems